Merrill McPeak A.'s Insider Trades & SAST Disclosures
Merrill McPeak A.'s most recent trade in Research Solutions Inc was a trade of 50,000 Option to purchase common stock done . Disclosure was reported to the exchange on Nov. 12, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Merrill McPeak A..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Research Solutions Inc | Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2024 | 50,000 | 50,000 | - | - | Option to purchase common stock | |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 50,000 | 50,000 | - | - | Deferred Restricted Stock Unit | |
| Iovance Biotherapeutics Inc | Merrill McPeak A. | Director | Purchase of securities on an exchange or from another person at price $ 9.15 per share. | 20 Feb 2024 | 250,000 | 320,150 (0%) | 0% | 9.2 | 2,287,500 | Common Stock |
| Research Solutions Inc | McPeak Merrill A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 50,000 | 50,000 | - | - | Option to purchase common stock | |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 51,955 | 51,955 | - | - | Deferred Restricted Stock Unit | |
| Research Solutions Inc | Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2023 | 50,000 | 0 | - | - | Option to purchase common stock | |
| Research Solutions Inc | Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.15 per share. | 16 Jan 2023 | 50,000 | 284,608 | - | 1.2 | 57,500 | Common Stock |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Purchase of securities on an exchange or from another person at price $ 6.15 per share. | 21 Dec 2022 | 10,000 | 70,150 (0%) | 0% | 6.2 | 61,500 | Common Stock |
| Research Solutions Inc | Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2022 | 50,000 | 50,000 | - | - | Option to purchase common stock | |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Purchase of securities on an exchange or from another person at price $ 6.31 per share. | 29 Nov 2022 | 10,000 | 238,633 (0%) | 0% | 6.3 | 63,100 | Common Stock |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Purchase of securities on an exchange or from another person at price $ 6.18 per share. | 28 Nov 2022 | 10,000 | 228,633 (0%) | 0% | 6.2 | 61,800 | Common Stock |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2022 | 40,000 | 0 | - | - | Stock Option (right to buy) | |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.65 per share. | 23 Aug 2022 | 40,000 | 60,150 (0%) | 0% | 5.7 | 226,000 | Common Stock |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 51,204 | 51,204 | - | - | Deferred Restricted Stock Unit | |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Purchase of securities on an exchange or from another person at price $ 6.80 per share. | 31 May 2022 | 10,000 | 218,633 (0%) | 0% | 6.8 | 68,000 | Common Stock |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Purchase of securities on an exchange or from another person at price $ 6.84 per share. | 31 May 2022 | 10,000 | 20,150 (0%) | 0% | 6.8 | 68,400 | Common Stock |
| Research Solutions Inc | Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2022 | 50,000 | 50,000 | - | - | Option to purchase common stock | |
| Research Solutions Inc | Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.19 per share. | 05 Nov 2021 | 50,000 | 234,608 | - | 1.2 | 59,500 | Common Stock |
| Research Solutions Inc | Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 50,000 | 0 | - | - | Warrant to purchase common stock | |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Research Solutions Inc | Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.25 per share. | 07 Jun 2021 | 7,500 | 184,608 | - | 1.3 | 9,375 | Common Stock |
| Research Solutions Inc | Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 7,500 | 0 | - | - | Common Stock Warrants (right to buy) | |
| Research Solutions Inc | Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2020 | 50,000 | 50,000 | - | - | Option to purchase common stock | |
| Research Solutions Inc | Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2020 | 50,000 | 0 | - | - | Warrant to purchase common stock | |
| Research Solutions Inc | Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.25 per share. | 09 Oct 2020 | 50,000 | 177,108 | - | 1.3 | 62,500 | Common Stock |
| Iovance Biotherapeutics Inc | Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges